细胞色素P450同工酶在外源物代谢中的作用

[1] The aryl- hydrocarbon receptor,butnot the aryl- hydrocarbon receptor nucleartranslocator protein,is rapidly depleted inhepatic and nonhepatic culture cells exposed to 2 ,3,7,8 - tetrachlordibenzo- p- dioxin. Pollenz RS. Molecular Pharmacology . 1996

[2] Clinically relevant pharmacology ofselective serotonin reuptake inhibitors.Anoverview with emphasis on pharmacokinetics andeffects on oxidative drug metabolism. Preskon SH. Clinical Pharmacokinetics . 1997

[3] The CYP2 D6genotype predicts the oral clearanceof the neuroleptic agents perphenazine andzuclopenthixol. Jerling M,Dahl ML,Aberg- Wistedt A,et al. Clinical Pharmacology and Therapeutics . 1996

[4] Metabolic activation of 4- ipomeanol bycomplementary DNA- expressed humancytochromes P- 45 0 :evidence for species- specificmetabolism. Czerwinski M,Mclemore TL,Philpot RM,etal. Cancer Research . 1991

[5] Association of low CYP3A activity with p5 3mutation and CYP2 D6activity with Rb mutationin human bladder cancer. Romkes M,Chern HD,Lesnick TG,et al. Carcinogenesis . 1996

[6] Role of human microsomal and humancomplementary DNA- expressed cytochromesP45 0 1A2 and P45 0 3A4in the bioactivation ofaflatoxin B1. Gallagher EP,Wienkers L C,Stapleton PL,etal. Cancer Research . 1994

[7] Interindividual variations in human livercytochrome P- 45 0 enzymes involved in theoxidation of drugs,carcinogens and toxicchemicals:studies with liver microsomes of 30Japanese and Caucasians. Shimada T,Yamazaki H,Mimura M,et al. Journal of Pharmacology and Experimental Therapeutics . 1994

[8] Toxicology[C]. 2002年中日毒理学和药理学联合研讨会,2002

[9] Toxicology[C]. 2002年中日毒理学和药理学联合研讨会,2002

[10] P45 0 Superfamily:update on new sequences,gene mapping,accession numbers andnomenclature. Nelson DR,Koymans L,Kamatahi T,et al. Pharmacogenetics . 1996

[1] The aryl- hydrocarbon receptor,butnot the aryl- hydrocarbon receptor nucleartranslocator protein,is rapidly depleted inhepatic and nonhepatic culture cells exposed to 2 ,3,7,8 - tetrachlordibenzo- p- dioxin. Pollenz RS. Molecular Pharmacology . 1996

[2] Clinically relevant pharmacology ofselective serotonin reuptake inhibitors.Anoverview with emphasis on pharmacokinetics andeffects on oxidative drug metabolism. Preskon SH. Clinical Pharmacokinetics . 1997

[3] The CYP2 D6genotype predicts the oral clearanceof the neuroleptic agents perphenazine andzuclopenthixol. Jerling M,Dahl ML,Aberg- Wistedt A,et al. Clinical Pharmacology and Therapeutics . 1996

[4] Metabolic activation of 4- ipomeanol bycomplementary DNA- expressed humancytochromes P- 45 0 :evidence for species- specificmetabolism. Czerwinski M,Mclemore TL,Philpot RM,etal. Cancer Research . 1991

[5] Association of low CYP3A activity with p5 3mutation and CYP2 D6activity with Rb mutationin human bladder cancer. Romkes M,Chern HD,Lesnick TG,et al. Carcinogenesis . 1996

[6] Role of human microsomal and humancomplementary DNA- expressed cytochromesP45 0 1A2 and P45 0 3A4in the bioactivation ofaflatoxin B1. Gallagher EP,Wienkers L C,Stapleton PL,etal. Cancer Research . 1994

[7] Interindividual variations in human livercytochrome P- 45 0 enzymes involved in theoxidation of drugs,carcinogens and toxicchemicals:studies with liver microsomes of 30Japanese and Caucasians. Shimada T,Yamazaki H,Mimura M,et al. Journal of Pharmacology and Experimental Therapeutics . 1994

[8] Toxicology[C]. 2002年中日毒理学和药理学联合研讨会,2002

[9] Toxicology[C]. 2002年中日毒理学和药理学联合研讨会,2002

[10] P45 0 Superfamily:update on new sequences,gene mapping,accession numbers andnomenclature. Nelson DR,Koymans L,Kamatahi T,et al. Pharmacogenetics . 1996